Critically ill patients in the hospital are at high risk for developing venous thromboembolism (VTE). The 2011 PROTECT trial compared the two most common drug strategies used to prevent VTE — unfractionated heparin (UFH) and dalteparin, a low-molecular-weight heparin (LMWH) — and found no difference between the two groups in the primary endpoint of the trial, leg deep-vein thrombosis….
Economic Study Finds VTE Prophylaxis with Low-Molecular-Weight Heparin Cost Effective
FDA Grants New Indication For Apixaban
The FDA today approved an expanded indication for the oral anticoagulant apixaban (Eliquis, Bristol-Myers Squibb and Pfizer). Apixaban will now be indicated for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE (collectively known as venous thromboembolism) after initial therapy. … Click here to…
Apixaban Gains Indication For DVT Prophylaxis After Knee And Hip Replacement Surgery
The FDA has approved a new indication for apixaban (Eliquis), the anticoagulant drug manufactured by Bristol-Myers Squibb and Pfizer. The new indication is for the prophylaxis of deep vein thrombosis (DVT) in patients who have undergone hip or knee replacement surgery. DVT can lead to the life-threatening condition of pulmonary embolism (PE). The DVT prophylaxis indication joins the previously…
Rivaroxaban Gains FDA Indications For The Treatment And Prevention Of DVT And PE
The FDA today expanded the indication for rivaroxaban (Xarelto, Johnson & Johnson) to include the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and to reduce the risk of recurrent DVT and PE. The oral anticoagulant is already approved to reduce the post-surgical risk of DVT and PE after hip and knee replacement…
Recent Comments